Targeted Oncologics ISO Companion Diagnostics To Find Attractive Patients

The molecularly targeted oncologics that have energized oncology drug development and treatment over the last decade have sparked a secondary boom in companion diagnostics. After all, a drug for a tumor expressing a particular receptor profile is not particularly useful unless physicians can identify patients with that profile.